Zhongkang CMH China Pharmaceutical Out-of-Hospital Retail Market Analysis - Omni-channel, April 2024 data is freshly released! (Pay attention to Xinkang Circle, reply to [Omnichannel April], you can get the full report)
From January to April 2024, the scale of drug sales in China's pharmaceutical retail market reached 165.5 billion yuan, a year-on-year increase of 1.5%, with a steady increase. In terms of channels, the scale of retail pharmacies (including O2O) accounted for 87.8%, with a growth rate of 1.1%, and the importance of e-commerce B2C was further enhanced, accounting for 12.2% and a growth rate of 4.6%.
Prescription drugs have a higher share in retail pharmacies and B2C, and the growth rate is higher than that of over-the-counter drugs; The share of over-the-counter drugs in O2O is relatively high, and both prescription drugs and over-the-counter drugs have a rapid growth rate.
The category pattern in different channels is very different, and the channel attributes are prominent
- Daily drugs and standing medicines, such as colds and heat, gastrointestinal diseases and vitamin and mineral supplements, entered the top 10 in all channels;
- Retail pharmacies show professionalism, and oncology drugs, cardiovascular and cerebrovascular, and hypertension drugs rank high;
- B2C is easy to stock up on drugs and has privacy, and skin drugs and urinary system drugs rank among the top three;
- O2O is convenient, fast and time-sensitive, and the growth rate of cold medicines, cough and expectorants, oral and throat drugs, and systemic anti-infective drugs is prominent.
Note: Retail pharmacies are national data; B2C includes Tmall + JD.com;
O2O includes the two major platforms of Meituan + Ele.me, which are 70 cities with sales + 70% direct delivery to stores.
Pay attention to the new health industry and reply to [Omnichannel April] to get the full report